Furthermore, DTLL might suppress pancreatic tumor progression by EGFR/HER2-dependent blockage of AKT/mTOR-signaling and PD-L1/PD1-mediated escape from immunosurveillance in PDAC25. The gene discussed is AKT1; the disease is pancreatic neoplasm.